Asahi Kasei Pharma Corp - Strategic SWOT Analysis Review

Asahi Kasei Pharma Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description - A detailed description of the company’s operations and business divisions.
• Corporate strategy - The publisher's summarization of the company’s business strategy.
• SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives’ employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Asahi Kasei Pharma Corp (Asahi Kasei Pharma), a subsidiary of Asahi Kasei Corp, manufactures and markets diagnostic reagents, prescription drugs, and enzymes for diagnostic reagents. Its prescription drugs are used in the treatment of osteoporosis pain, disseminated intravascular coagulation, bone loss, dysuria accompanying benign prostatic hyperplasia, proteinuria in nephrotic syndrome, nocturia, and lupus nephritis, among others. Asahi Kasei Pharma offers assay kits for glycemic control and to detect prediabetes. The company’s pipeline products are intended for the treatment of chemotherapy-induced peripheral neuropathy, osteoporosis with high risk of fracture, Lupus nephritis and nephrotic syndrome, and severe sepsis with coagulopathy, among others. It has facilities in Shizuoka, and Nagoya, Japan. Asahi Kasei Pharma is headquartered in Tokyo, Japan.

Asahi Kasei Pharma Corp Key Recent Developments

• Oct 14022: C-Path's Transplant Therapeutics Consortium receives EMA Draft Qualification Opinion for the iBox Scoring System
• Oct 13022: Asahi Kasei Pharma to Sponsor Research for Drug Discovery Research and Technology: Open Innovation 2023
• Jun 06022: Asahi Kasei Appoints Senior Industry Expert Gene Martin as Agent Representing its Products in the United States

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors’ business structure and strategies with the publisher's detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.